|
|
|
|
bevacizumab
A monoclonal antibody used in the treatment of colorectal cancer that has spread. It is also being studied in the treatment of other types of cancer. It may prevent the growth of new blood vessels from surrounding tissue to a solid tumor. Also called Avastin. (National Cancer Institute)
Old enemy, new hope 17 Mar 2005
...difference to survival time. Avastin (bevacizumab), is manufactured by Roche and Erbitux (cetuximab), by Merck. It was Erbitux that ... Times Online,
Adding Bevacizumab in First-Line Chemotherapy Regimen Improves ... Mar 14, 2005
...and Roche today announced that an interim analysis of a Phase III study of Avastin(TM)(bevacizumab) plus paclitaxel and carboplatin chemotherapies in first ... RxPG NEWS,
Lung cancer, Avastin extends survival Mar 16, 2005
An interim analysis of a Phase III study of Avastin ( Bevacizumab ) in combination with Paclitaxel and Carboplatin in advanced, non-small cell lung cancer ... Xagena.it,
Avastin's Survival Data In NSCLC Sends Genentech Soaring, Again Mar 15, 2005
The interim analysis of Avastin (bevacizumab) plus paclitaxel and carboplatin in first-line non-squamous, NSCLC improved overall survival by 2.3 months, or 23 ... BioWorld Online (subscription)
Avastin™ Improves Survival in Advanced Non-Small Cell Lung ... Mar 15, 2005
According to preliminary results recently released by the National Cancer Institute (NCI), the addition of Avastin™ (bevacizumab) to standard chemotherapy ... Cancer Consultants (press release),
AVASTIN- SHOWS EXCITING RESULTS FOR LUNG CANCER Mar 14, 2005
Avastin, known generically as bevacizumab, is a monoclonal antibody -- a laboratory-made immune system protein designed to interfere with vascular endothelial ... Express Newsline,
REVOLUTIONARY DRUG KILLS CANCER BY CUTTING ITS Mar 11, 2005
British patients with previously untreated advanced bowel cancer have the potential to benefit from today's launch of Avastin (bevacizumab). ... ITNews,
Genentech<DNA.N> Avastin aids lung cancer survival Mar 14, 2005
Patients given Avastin, known generically as bevacizumab, in combination with the standard chemotherapy drugs paclitaxel and carboplatin had a median overall ... Reuters AlertNet,
Roche’s Avastin launched in Europe Mar 14, 2005
14/03/2005 - Roche has started the roll-out its colorectal cancer treatment Avastin (bevacizumab) – the first drug to reach the market that works by ... Drug Researcher.com,
Avastin® May Be Effective in Ovarian Cancer Mar 9, 2005
Researchers from the University of California Irvine have published a case report documenting activity of Avastin® (bevacizumab, rhu MAB VEGF) in a patient ... Cancer Consultants (press release),
Research trial allows breast cancer patients to keep hair Mar 7, 2005
...to keep their hair. The trial includes a combination drug therapy of Herceptin and Bevacizumab. "This trial involves biological ... Orlando Business Journal,
TAT2005 - 3rd International Symposium on Targeted Anticancer ... Mar 4, 2005
The first representatives of this new generation of cancer therapies, including bevacizumab (Avastin®), cetuximab (Erbitux®) and bortezomib (Velcade®), have ... Medical News Today,
CANCER TREATMENT AVASTIN SET TO ROLL OUT IN EUROPE Mar 13, 2005
...with advanced (metastatic) colorectal cancer are now eligible to receive the unique new life extending cancer medicine, Avastin(R) (bevacizumab, rhuMAb-VEGF). ... Money Plans,
Avastin Proven Effective Even in Advanced Colorectal Cancer ... Feb 28, 2005
Avastin (bevacizumab, rhuMAb-VEGF), when added to a less aggressive form of chemotherapy, prolonged the time the cancer was not growing by an extra four months ... Presseportal (Pressemitteilung),
New Treatment for Wet Age-Related Macular Degeneration Shows ... Mar 3, 2005
...in leakage from the abnormal blood vessels, and we observed a restoration of normal macular anatomy." Avastin(TM), also known as bevacizumab, is manufactured ... Business Wire (press release),
Genentech Announces Strategic Updates at Investment Meeting Mar 4, 2005
Results from the Phase III Eastern Cooperative Oncology Group (ECOG) 4599 study of Avastin(TM) (bevacizumab) in first-line non-small cell lung cancer (NSCLC ... PR Newswire (press release)
Antiangiogenic Therapy a Two-Trick Pony? Mar 1, 2005
...more than 800 patients with metastatic colorectal cancer revealed that when combined with chemotherapy, the anti-VEGF antibody bevacizumab, increased survival ... Journal of American Medical Association (subscription),
Provenge with Avastin Impacts PSA Doubling Time in Patients with ... Feb 22, 2005
Dendreon Corporation announced that results from its NCI-sponsored Phase 2 study of Provenge(R), in combination with Avastin(TM) (bevacizumab), increased PSA ... Medical News Today,
Archives: The following articles may no longer be available on the web. If you want to inquire on a particular article, please contact the source publication (listed in parentheses).
<**results**>
Avastin Wallops Q2 Estimates; Genentech Cracks Billion Mark Jul 8, 2004
Avastin. Trouncing consensus estimates of $85 million, Avastin (bevacizumab) pulled in $133 million in its first full quarter of sales. ... BioWorld Online (subscription) -
INCREASE IN PRODUCT SALES DRIVES GENENTECH'S Q2 REVENUE Jul 8, 2004
The company generated $133 million in sales of its colorectal cancer therapy Avastin (bevacizumab) during the quarter, the product’s first full quarter on ... Pharmexec (press release) -
Avastin-Tarceva Combo Provides 'One-Two' Punch Against Lung Cancer Jun 7, 2004
85 percent of the 40 patients with advanced non-small cell lung cancer (NSCLC) who entered the Phase I/II trial of a combined regimen of bevacizumab (Avastin TM ... Science Daily (press release) -
Roche, GSK ramp up production Jun 24, 2004
The new facilities will be used to make two antibody-based drugs for cancer – Herceptin (trastuzumab) and Avastin (bevacizumab) – that have been developed ... In Pharma, France -
Roche plans biotech plants Jun 24, 2004
The new facilities will be used to produce monoclonal antibodies for the anticancer medicines Avastin (bevacizumab) and Herceptin (trastuzumab). ... Chemical & Engineering News -
Genentech Presents Data From Broad Avastin Clinical Trial Program ... Jun 8, 2004
...(NYSE: DNA - News) today announced results from a Phase II study evaluating the combination of Avastin(TM) (bevacizumab) and gemcitabine chemotherapy in the ... Yahoo News (press release) -
Dual drugs may help treat kidney cancer Jun 7, 2004
The patients, each of whom had lost a kidney to cancer that had spread, received bevacizumab, which blocks the growth of blood vessels in tumors, and erlotinib ... Times Picayune, LA -
Special therapies promising against tough cancers Jun 11, 2004
The two medicines, bevacizumab (Avastin) and erlotinib (Tarceva), are produced by the US laboratory Genentech and have been administered in 40 cases, of which ... IAfrica South African News, South Africa -
QUICK STUDY : A weekly digest of new research on major health ... Jun 14, 2004
...with metastatic colorectal cancer to receive the normal chemotherapy regimen (irinotecan, fluorouracil and leucovorin), plus either bevacizumab (Avastin) or a ... Washington Post, DC -
OSI Pharmaceuticals and Genentech Enter into Co-Promotion and ... Jun 16, 2004
Genentech is leading clinical development programs for Rituxan(R) (Rituximab), Herceptin(R) (Trastuzumab), and Avastin(TM) (bevacizumab) and markets all three ... Business Wire (press release), CA -
Health Highlights: June 6, 2004 Jun 6, 2004
The post-operative patients in the clinical trial had their tumors treated with a combined regimen of bevacizumab (Avastin) and erlotinib (Tarceva). ... Atlanta Journal Constitution (subscription), GA -
Camptosar in combination with targeted therapies shows survival ... Jun 7, 2004
...with a combination of CAMPTOSAR (irinotecan HCL injection) plus bolus 5-flouruocil/leucovrin (5-FU/LV) (IFL) and Avastin (bevacizumab) prolongs survival in ... EurekAlert, DC -
Resources from the National Cancer Institute on bevacizumab:
Cancer.gov - Digest Page: Treatment Referral Center Trial of ... Digest Page: Treatment Referral Center Trial of Bevacizumab (Avastin™).
Updated: 02/20/2004 NCI Press Materials NCI Materials Current ...
Cancer.gov Treatment Referral Center Trial of Bevacizumab A collection of material about a clinical
trial that is evaluating bevacizumab (Avastin™), an investigational ...
Cancer.gov Bevacizumab (Avastin™) for Metastatic Colorectal Cancer, Posted Date: Tuesday,
June 10, 2003 Updated: 02/23/2004. print version. ... 1. What is bevacizumab? ...
Cancer.gov Contact the NCI Press Office, NCI Planning Study of Bevacizumab (Avastin™) for
Metastatic Colorectal Cancer, Posted Date: Friday, June 06, 2003. print version. ...
Cancer.gov - Dictionary ...not cancer. ß-hCG is being studied in the treatment of Kaposi’s
sarcoma. bevacizumab (be-vuh-SIZ-uh-mab) A monoclonal ...
Cancer.gov Phase II Pilot Study of Bevacizumab, Docetaxel, and Doxorubicin in Patients
With Previously Untreated Inflammatory or Locally Advanced Breast Cancer. ...
Cancer.gov Phase II Treatment Referral Center Protocol of Bevacizumab, Fluorouracil, and
Leucovorin Calcium in Patients With Stage IV Colorectal Cancer That Has ...
Cancer.gov Phase II Study of APC8015 (Provenge) and Bevacizumab in Patients With
Progressive Prostate Cancer. Date Last Modified: 2004-01-02. ...
HIV and AIDS Malignancy Branch (HAMB) Patient-volunteers are being recruited for a pilot clinical trial to test the experimental
monoclonal humanized antibody bevacizumab in patients with Kaposi's ...
Cancer.gov Phase III Randomized Study of Interferon alfa-2b With or Without Bevacizumab in
Patients With Advanced Renal Cell Carcinoma. Date Last Modified: 2003-11-05. ...
|
|
|
